retatrutide dosage clinical trials retatrutide trial weight loss data Results: 24% in 48 Weeks dose: the complete guide – Retatrutide Dosing: Early Clinical Trial

Importantly, Retatrutide's unique triple receptor agonismtargeting GLP-1, GIP, and glucagon receptorsappears well-tolerated, with adverse events largely consistent with known effects from the broader GLP-1 class, primarily mild gastrointestinal symptoms such as nausea, decreased appetite, and occasional diarrhea, typically resolving within a few weeks of initiation

As always, coordination with prescribing physicians remains important

When GLP1s suppress appetite, the risk of unintended muscle loss is real unless resistance training and adequate protein intake are prioritized

For constipation, increase fiber intake gradually, stay well hydrated, and consider a magnesium supplement (magnesium citrate works well)